Renaissance Technologies’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Renaissance Technologies’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-361,400	Closed	-$14.8M	–	4002
2024 Q2	$14.8M	Sell	361,400 -88,000	-20%	-$3.66M	0.03%	732
2024 Q1	$19M	Buy	449,400 +209,900	+88%	+$8.82M	0.03%	662
2023 Q4	$10.2M	Buy	+239,500	New	+$6.88M	0.02%	943
2022 Q2	–	Sell	-9,900	Closed	-$347K	–	4649
2022 Q1	$347K	Buy	+9,900	New	+$289K	﹤0.01%	3403
2021 Q3	–	Sell	-56,200	Closed	-$1.44M	–	3939
2021 Q2	$1.44M	Buy	+56,200	New	+$805K	﹤0.01%	2466

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Renaissance Technologies's CERE Position: Q3 2024 in Review

Renaissance Technologies sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 361,400 shares — an estimated $14.8M sold.

Renaissance Technologies first reported a position in CERE in Q2 2021 and held it in 5 quarters. The position peaked at $19M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Renaissance Technologies reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Renaissance Technologies sold 361,400 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $14.8M.
Renaissance Technologies first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Renaissance Technologies's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $19M in Q1 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.